Climb Bio Dividends and Buybacks
Dividend criteria checks 0/6
Climb Bio does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-84.7%
Buyback Yield
| Total Shareholder Yield | -84.7% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CLYM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLYM's dividend payments have been increasing.
Dividend Yield vs Market
| Climb Bio Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CLYM) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (CLYM) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate CLYM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLYM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CLYM's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CLYM has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 11:13 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Climb Bio, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Yatin Suneja | Guggenheim Securities, LLC |
| Marc Goodman | Leerink Partners LLC |